April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Intraocular Cytokines and Growth Factors in Neovascular Age-Related Macular Degeneration and the Effect of Therapy with Ranibizumab
Author Affiliations & Notes
  • M. Funk
    Department of Ophthalmology,
    Medical University Vienna, Vienna, Austria
  • D. Karl
    Department of Ophthalmology,
    Medical University Vienna, Vienna, Austria
  • M. Georgopoulos
    Department of Ophthalmology,
    Medical University Vienna, Vienna, Austria
  • T. Benesch
    Institute of Medical Statistics,
    Medical University Vienna, Vienna, Austria
  • S. Sacu
    Department of Ophthalmology,
    Medical University Vienna, Vienna, Austria
  • K. Polak
    Department of Ophthalmology,
    Medical University Vienna, Vienna, Austria
  • G. Zlabinger
    Institute of Immunology,
    Medical University Vienna, Vienna, Austria
  • U. Schmidt-Erfurth
    Department of Ophthalmology,
    Medical University Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships  M. Funk, None; D. Karl, None; M. Georgopoulos, None; T. Benesch, None; S. Sacu, None; K. Polak, None; G. Zlabinger, None; U. Schmidt-Erfurth, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2331. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Funk, D. Karl, M. Georgopoulos, T. Benesch, S. Sacu, K. Polak, G. Zlabinger, U. Schmidt-Erfurth; Intraocular Cytokines and Growth Factors in Neovascular Age-Related Macular Degeneration and the Effect of Therapy with Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2331.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate concentrations of growth factors and inflammatory cytokines in eyes with neovascular age-related macular degeneration (AMD) before and during therapy with intravitreal ranibizumab and to identify associations with disease activity.

Methods: : In a prospective clinical trial 28 eyes of patients with neovascular AMD were compared to 28 eyes of age-matched cataract patients as control. Ranibizumab was administered intravitreously once at baseline and re-treatments were given at monthly visits if OCT revealed macular edema or if vision loss had occurred. Aqueous humor samples were taken each time intravitreal interventions were performed. Follow-up was 12 months. Luminex multiplex assays were used for measurement of 29 different growth factors and cytokines.

Results: : A significantly increased expression of VEGF (p=0.033) and a significantly decreased expression of PDGF (p=0.038) was measured in the aqueous humor of eyes with neovascular AMD. Furthermore, a significant decrease of VEGF (p<0.001) was observed after intravitreal injection of ranibizumab along with significant changes in visual acuity and central retinal thickness (p=0.039 and p<0.001). During follow-up with a flexible regimen, a correlation was identified between increased VEGF levels and persistent or recurrent macular edema. Changes in PDGF levels were strongly associated with alterations in VEGF concentration.

Clinical Trial: : European clinical database EUDRACT-2006-005684-26

Keywords: choroid: neovascularization • aqueous • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×